Latest updates for Abbv:ca
Fresh curated links around ABBV:CA are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
- Atea Pharmaceuticals: I'm Optimistic Ahead Of Critical HPV Catalyst
- ABIVAX Société Anonyme (ABVX) Discusses Positive Phase III ABTECT Trial Results for Obefazimod in Ulcerative Colitis - S
- Is ABIVAX Société Anonyme (ABVX) A Good Stock To Buy Now?
Post angles to try
Fresh articles and ideas
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
ABIVAX Société Anonyme (ABVX) Discusses Positive Phase III ABTECT Trial Results for Obefazimod in Ulcerative Colitis - S...
ABIVAX Société Anonyme (ABVX) Discusses ABTECT Maintenance Part 2 Results and Updated Obefazimod Safety and Efficacy Dat...
Abivax: Downgrading To 'Hold' As NDA Obefazimod Still Underway Despite Major Safety Risks
Is AbbVie a Buy After Its Purchase of Apogee?
The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?
<![CDATA[AbbVie to Acquire Apogee Therapeutics in $10 Billion Deal]]>
This Stock Is Up 1,000% Over the Past Year. Is There More Upside Ahead?
A recent dip may turn out to be a great opportunity.
Dividend Kings In Focus: AbbVie
Updated on July 9th, 2026 by Josh Arnold We believe that long-term investors should focus on the highest-quality dividend-growth stocks. These are companies with long histories of...
In a Volatile Market, This Dividend Growth Stock Is Worth Every Penny of $1,000
Abbott Labs could rally in a downturn and has a long-term growth catalyst to boot.
Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500?
For a solid yield and strong upside potential, this pharmaceutical stock is worth considering.
AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy?
In the past five years, this top healthcare stock has risen by close to 130%.
<![CDATA[Pharmaceutical Executive Daily: AbbVie Acquires Apogee Therapeutics for $10.9 Billion]]>
Abivax stock reverses course, trades down 40% despite positive ulcerative colitis trial
StockWatch: New UC Data Sparks Smoother Sailing for Abivax
Less than a month after its stock roller-coastered on safety signals associated with its late-stage ulcerative colitis (UC) drug candidate obefazimod, shares of Abivax (Euronext Pa...
AbraSilver: RIGI Turns Diablillos Into A Scarce Silver Development Asset
StockWatch: Abivax Survives a Roller Coaster Week
Abivax’s stock plummeted after analysts from Jefferies, Morgan Stanley, Truist Securities, and Wedbush Securities raised as a safety concern a portion of data showing malignancies...
AbCellera Biologics Inc. (ABCL) Presents at Jefferies Global Healthcare Conference 2026 Transcript
AbbVie Inc. (ABBV) Hits New Milestone with Venetoclax on Chronic Lymphocytic Leukemia (CLL) Treatment
Absci Corporation (ABSI) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.